Claims
- 1. A compound of Formula II ##STR178## wherein B is 1H-tetrazol-5-yl; wherein each of Y.sub.m and Y.sub.n is a spacer group independently selected from one or more groups of the formula ##STR179## wherein each of R.sup.27 and R.sup.28 is independently selected from hydrido, alkyl having from one to five carbon atoms, cycloalkyl having from three to ten carbon atoms, halo, haloalkyl wherein the alkyl portion thereof contains from one to five carbon atoms, phenyl, benzyl, hydroxy, hydroxyalkyl wherein the alkyl portion thereof contains from one to five carbon atoms, alkoxy wherein the alkyl portion thereof contains from one to five carbon atoms, phenoxy, alkoxyalkyl wherein the alkyl portion thereof contains from one to five carbon atoms, benzyloxy, cyano, alkanoyl wherein the alkyl portion thereof contains from one to five carbon atoms, ##STR180## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from hydrido, alkyl having from one to five carbon atoms and phenyl; wherein R.sup.27 and R.sup.28 may be taken together to form oxo or exomethylene; wherein each of R.sup.29 and R.sup.30 is independently selected from hydrido, alkyl having from one to five carbon atoms, haloalkyl wherein the alkyl portion thereof contains from one to five carbon atoms, phenyl, hydroxyalkyl wherein the alkyl portion thereof contains from one to five carbon atoms and alkoxyalkyl wherein the alkyl portion thereof contains from one to five carbon atoms; wherein each of m and n is a number independently selected from zero to three, inclusive;
- wherein each X and T is one or more groups independently selected from hydrido, alkyl having from one to five carbon atoms, cycloalkyl having from three to ten carbon atoms, cycloalkylalkyl wherein the alkyl portion thereof contains from one to five carbon atoms and the cycloalkyl portion contains from three to ten carbon atoms, halo, haloalkyl wherein the alkyl portion thereof contains from one to five carbon atoms, alkenyl, cycloalkenyl, alkynyl, phenyl, benzyl, hydroxy, hydroxyalkyl wherein the alkyl portion thereof contains from one to five carbon atoms, alkoxy wherein the alkyl portion thereof contains from one to five carbon atoms, phenoxy, alkoxyalkyl wherein the alkyl portion thereof contains from one to five carbon atoms, benzyloxy, cyano, cyanoamino, alkanoyl wherein the alkyl portion thereof contains from one to five carbon atoms, mercapto, alkylthio wherein the alkyl portion thereof contains from one to five carbon atoms, arylthio, alkylsulfinyl wherein the alkyl portion thereof contains from one to five carbon atoms, alkylsulfonyl wherein the alkyl portion thereof contains from one to five carbon atoms, arylsulfinyl and arylsulfonyl, ##STR181## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from hydrido, alkyl having from one to five carbon atoms and phenyl; or a pharmaceutically-acceptable salt thereof.
- 2. Compound of claim 1 wherein each of Y.sub.m and Y.sub.n is a spacer group independently selected from one or more of alkyl having one to five carbon atoms, alkenyl, alkynyl, aryl selected from phenyl, biphenyl and naphthyl and aralkyl wherein the alkyl portion contains from one to five carbon atoms, any one of which spacer groups may be substituted at any substitutable position with one or more groups selected from alkyl having one to five carbon atoms, cycloalkyl having from three to ten carbon atoms, oxo, exomethylene, halo, haloalkyl wherein the alkyl portion contains from one to five carbon atoms, phenyl, benzyl, hydroxy, hydroxyalkyl wherein the alkyl portion contains from one to five carbon atoms, alkoxy wherein the alkyl portion contains from one to five carbon atoms, phenoxy, alkoxyalkyl wherein the alkyl portion contains from one to five carbon atoms, benzyloxy, cyano, alkanoyl wherein the alkyl portion contains from one to five carbon atoms, and amino and amido radicals of the formula ##STR182## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from hydrido, alkyl having one to five carbon atoms, phenyl and benzyl; wherein each of m and n is a number independently selected from zero to three, inclusive;
- wherein each X and T is one or more groups independently selected from hydrido, alkyl having one to five carbon atoms, cycloalkyl having from three to ten carbon atoms, cycloalkylalkyl wherein the cycloalkyl portion contains from three to ten carbon atoms and the alkyl portion contains one to five carbon atoms, halo, haloalkyl wherein the alkyl portion contains from one to five carbon atoms, alkenyl, cycloalkenyl, alkynyl, phenyl, benzyl, hydroxy, hydroxyalkyl wherein the alkyl portion contains from one to five carbon atoms, alkoxy wherein the alkyl portion contains from one to five carbon atoms, alkoxyalkyl wherein the alkyl portion contains from one to five carbon atoms, benzyloxy, cyano, cyanoamino, alkanoyl wherein the alkyl portion contains from one to five carbon atoms, mercapto, alkylthio wherein the alkyl portion contains from one to five carbon atoms, arylthio, alkylsulfinyl wherein the alkyl portion contains from one to five carbon atoms, alkylsulfonyl wherein the alkyl portion contains from one to five carbon atoms, arylsulfinyl and arylsulfonyl, and amino and amido radicals of the formula ##STR183## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from hydrido, alkyl having one to five carbon atoms, phenyl and benzyl; or a pharmaceutically-acceptable salt thereof.
- 3. Compound of claim 1 wherein each of Y.sub.m and Y.sub.n is a spacer group independently selected from one or more groups of the formula ##STR184## wherein each of R.sup.27 and R.sup.28 is independently selected from hydrido, alkyl having from one to five carbon atoms, cycloalkyl having from three to ten carbon atoms, halo, haloalkyl wherein the alkyl portion contains from one to five carbon atoms, hydroxy, hydroxyalkyl wherein the alkyl portion contains from one to five carbon atoms, alkoxy wherein the alkyl portion contains from one to five carbon atoms, alkoxyalkyl wherein the alkyl portion contains from one to five carbon atoms, alkanoyl wherein the alkyl portion contains from one to five carbon atoms, ##STR185## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from hydrido and alkyl having from one to five carbon atoms; wherein R.sup.27 and R.sup.28 may be taken together to form oxo or exomethylene; wherein each of R.sup.29 and R.sup.30 is independently selected from hydrido, alkyl having from one to five carbon atoms, haloalkyl wherein the alkyl portion contains from one to five carbon atoms, hydroxyalkyl wherein the alkyl portion contains from one to five carbon atoms and alkoxyalkyl wherein the alkyl portion contains from one to five carbon atoms; wherein each of m and n is a number independently selected from zero to three, inclusive;
- wherein each X and T is one or more groups independently selected from hydrido, alkyl having from one to five carbon atoms, cycloalkyl wherein the alkyl portion contains from one to five carbon atoms, halo, haloalkyl wherein the alkyl portion contains from one to five carbon atoms, phenyl, benzyl, hydroxy, hydroxyalkyl wherein the alkyl portion contains from one to five carbon atoms, alkoxy wherein the alkyl portion contains from one to five carbon atoms, phenoxy, alkoxyalkyl wherein the alkyl portion contains from one to five carbon atoms, benzyloxy, alkanoyl wherein the alkyl portion contains from one to five carbon atoms, ##STR186## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from hydrido and alkyl having from one to five carbon atoms; or a pharmaceutically-acceptable salt thereof.
- 4. Compound of claim 3 selected from compounds and their pharmaceutically-acceptable salts, of the group consisting of
- 6-chloro-.alpha.,2-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine-5-methanol;
- .alpha.,2-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine-5-methanol;
- 6-chloro-2-(1H-tetrazol-5-yl)-5-�(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 2-(1H-tetrazol-5-yl)-5-�(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 2-(1H-tetrazol-5-yl)-5-�methoxy(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- .alpha.,2-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine-6-methanol;
- 6-chloro-2-(1H-tetrazol-5-yl)-5-�methoxy(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 7-bromo-6-�2-methoxy-2-(1H-tetrazol-5-yl)ethyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-�2-methoxy-2-(1H-tetrazol-5-yl)ethyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 7-bromo-6-�2-(1H-tetrazol-5-yl)ethyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-�2-(1H-tetrazol-5-yl)ethyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-�2-hydroxy-2-(1H-tetrazol-5-yl)ethyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 5-�2-methoxy-2-(1H-tetrazol-5-yl)ethyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 7-bromo-6-�2-hydroxy-2-(1H-tetrazol-5-yl)ethyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 7-bromo-6-�3-methoxy-3-(1H-tetrazol-5-yl)propyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-�3-methoxy-3-(1H-tetrazol-5-yl)propyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 7-bromo-6-�3-(1H-tetrazol-5-yl)propyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-�3-(1H-tetrazol-5-yl)propyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-�3-hydroxy-3-(1H-tetrazol-5-yl)propyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 5-�3-methoxy-3-(1H-tetrazol-5-yl)propyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 7-bromo-6-�3-hydroxy-3-(1H-tetrazol-5-yl)propyl!-2-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-chloro-2,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 2,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-hydroxy-2,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-methoxy-2,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 2,6-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 2,7-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 5-chloro-2,6-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-chloro-3,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 3,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-hydroxy-3,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-methoxy-3,5-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 3,6-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 3,7-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 5-chloro-3,6-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-chloro-.alpha.,3-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine-5-methanol;
- .alpha.,3-bis(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine-5-methanol;
- 6-chloro-3-(1H-tetrazol-5-yl)-5-�(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 3-(1H-tetrazol-5-yl)-5-�(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 3-(1H-tetrazol-5-yl)-5-�methoxy(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 3-(1H-tetrazol-5-yl)-6-�(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 6-chloro-3-(1H-tetrazol-5-yl)-5-�methoxy(1H-tetrazol-5-yl)methyl!imidazo�1,2-a!pyridine;
- 6-chloro-5-�2-methoxy-2-(1H-tetrazol-5-yl)ethyl!-3-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 5-�2-methoxy-2-(1H-tetrazol-5-yl)ethyl!-3-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-chloro-5-�2-(1H-tetrazol-5-yl)ethyl!-3-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 5-�2-(1H-tetrazol-5-yl)ethyl!-3-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 5-�2-hydroxy-2-(1H-tetrazol-5-yl)ethyl!-3-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine;
- 6-�2-methoxy-2-(1H-tetrazol-5-yl)ethyl!-3-(1H-tetrazol-5-yl)imidazo�1,2-a!pyridine; and
- 6-chloro-5-�2-hydroxy-2-(1H-tetrazol-5-yl)ethyl!tetrazol-5-yl)imidazo�1,2-a!pyridine.
- 5.
- 5. A pharmaceutical composition comprising a therapeutically-effective amount of an active compound and a pharmaceutically-acceptable carrier or diluent, said active compound selected from a compound of claim 2.
- 6. A pharmaceutical composition comprising a therapeutically-effective amount of an active compound and a pharmaceutically-acceptable carrier or diluent, said active compound selected from a compound of claim 1.
- 7. A pharmaceutical composition comprising a therapeutically-effective amount of an active compound and a pharmaceutically-acceptable carrier or diluent, said active compound selected from a compound of claim 3.
- 8. A pharmaceutical composition comprising a therapeutically-effective amount of an active compound and a pharmaceutically-acceptable carrier or diluent, said active compound selected from a compound of claim 4.
- 9. A method to treat excitatory amino acid induced neurotoxic injury mediated by the NMDA receptor in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 2.
- 10. A method to treat excitatory amino acid induced neurotoxic injury mediated by the NMDA receptor in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 1.
- 11. A method to treat excitatory amino acid induced neurotoxic injury mediated by the NMDA receptor in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 3.
- 12. A method to treat excitatory amino acid induced neurotoxic injury mediated by the NMDA receptor in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 4.
- 13. The method of claim 12 for use in treating hypoxia, anoxia or ischemia.
- 14. The method of claim 13 for use in treating ischemia.
RELATED APPLICATION
This is a continuation of U.S. application Ser. No. 07/973,481, filed Nov. 9, 1992, abandoned which is a continuation-in-part of U.S. application Ser. No. 07/616,590, filed Nov. 26, 1990, abandoned, which is a continuation-in-part of Ser. No. 07/445,228 filed Dec. 4, 1989, abandoned.
US Referenced Citations (6)
Number |
Name |
Date |
Kind |
4450164 |
Bristol et al. |
May 1984 |
|
4501745 |
Kaplan et al. |
Feb 1985 |
|
4588732 |
Browne |
May 1986 |
|
4650796 |
George et al. |
Mar 1987 |
|
4657899 |
Rzeszotarski et al. |
Apr 1987 |
|
4746653 |
Hutchison et al. |
May 1988 |
|
Foreign Referenced Citations (6)
Number |
Date |
Country |
33094 |
Aug 1981 |
EPX |
120589 |
Oct 1984 |
EPX |
0 290 003 |
Nov 1988 |
EPX |
0 404 190 |
Dec 1990 |
EPX |
2581646 |
Nov 1986 |
FRX |
2606409 |
May 1988 |
FRX |
Non-Patent Literature Citations (5)
Entry |
S.M. Rothman et al, Annals of Neurology, vol. 19, No. 2, 105-111 (1986). |
M.N. Perkins et al, Neuroscience Lett., 23, 333 (1981). |
J. Davies et al, Neuroscience Lett., 21, 77 (1981). |
K. Matoba et al, "Structional Modification of Bioactive Compounds II. Synthesis of Aminophosphonic Acids", Chem. Pharm. Bull., 32, (10), 3918-3925 (1984). |
D.E. Murphy et al, J. Pharmacol. Exp. Ther., 240, (3), 778-784 (1987). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
973481 |
Nov 1992 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
616590 |
Nov 1990 |
|
Parent |
445228 |
Dec 1989 |
|